secwatch.observer — SEC 8-K summary
======================================

Issuer:     DAVITA INC. (DVA)
CIK:        0000927066
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0000927066-22-000131
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DaVita Q2 2022 EPS $2.30, revenue $2.93B; six-month net income down 27% YoY
---------------------------------------------------------------------------

- Q2 2022 revenue $2.927B, operating income $433M, diluted EPS $2.30 (vs Q1 2022 EPS $1.61).
- Six-month net income $387M ($3.90/sh) vs $531M ($4.72/sh) in prior year, down 27%.
- U.S. normalized non-acquired treatment growth was -1.9% YoY; per-day treatments up 0.9% QoQ.
- Patient care costs per treatment improved to $247.14 (Q2) from $252.61 (Q1); G&A rose to $241M.
- Repurchased 3.9M shares at $95.56 in Q2; additional 0.9M at $82.94 in July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/927066/000092706622000131/0000927066-22-000131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/927066/000092706622000131/dva-20220801.htm
  HTML page:      https://secwatch.observer/filing/0000927066-22-000131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer